Positive Results from Cardiovascular BioTherapeutics, Inc.'s Phase I No-Option Heart Disease Clinical Trial Will Be Presented at the American Heart Association's Annual Meeting

LAS VEGAS--(BUSINESS WIRE)--On the heels of FDA authorization to initiate Phase II clinical trials for severe coronary heart disease patients, CardioVascular BioTherapeutics, Inc. (OTCBB: CVBT) today announced that findings from its initial clinical protocol for its protein drug candidate will be presented by Dr. Lynne Wagoner at the American Heart Association’s Scientific Session to be held Nov. 4-7 in Orlando, Florida.